- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02448875
Clinical Evaluation of Visco-Assisted CyPass® Micro-Stent Implantation in Patients With Open Angle Glaucoma (ViscoPass)
Randomized, Prospective Clinical Evaluation of the Safety and Effectiveness of Visco-Assisted CyPass® Implantation in Patients With Open Angle Glaucoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study was conducted in 2 phases. Only one eye per subject was treated for each independent phase.
Dose Selection Phase (Cohort 1): Subjects were randomized in a 1:1:1 ratio and implanted with either a CyPass Micro-Stent with targeted delivery of 30 microliters (μl) ophthalmic 5 viscoelastic, a CyPass Micro-Stent with targeted delivery of 60 μl of ophthalmic viscoelastic, or a CyPass Micro-Stent without adjunct viscoelastic in the study eye.
Expansion Phase (Cohort 2): Subjects were randomized in a 1:1 ratio and implanted with either the CyPass Micro-Stent without adjunct viscoelastic or the CyPass Micro-Stent with 60 μl of ophthalmic viscoelastic (based on Dose Selection results). Subjects were randomized to treatment on the day of their surgical procedure. A total of 9 scheduled visits were planned including Screening (Day -45 to -2), Baseline (Day -15 to -1), Surgery (Day 0), 1 Day (Day 1), 1 Week (Day 5-9), 1 Month (Day 21-35), 3 Month (Day 70-98), 6 Month (Day 150-210), and 12 Month (Day 330-420) visits. The total expected duration of participation for each subject was up to 13 months.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Lubeck, Germany
- Transcend Medical Investigative Site
-
Mainz, Germany
- Transcend Medical Investigative Site
-
Neubrandenburg, Germany
- Transcend Medical Investigative Site
-
-
-
-
-
Panama City, Panama
- Transcend Medical Investigative Site
-
-
-
-
-
Warsaw, Poland
- Transcend Medical Investigative Site
-
-
-
-
-
Madrid, Spain
- Transcend Medical Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of open angle glaucoma;
- Unmedicated IOP between 21 - 36 mmHg, inclusive;
- Normal angle anatomy at site of intended CyPass Micro-Stent implantation.
Exclusion Criteria:
- Advanced glaucoma;
- Prior incisional glaucoma surgery;
- Acute angle closure, traumatic, congenital, malignant, uveitic or neovascular glaucoma;
- Clinically significant ocular pathology other than glaucoma.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: CyPass
CyPass Micro-Stent without adjunct viscoelastic implanted in the study eye
|
Small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye in order to reduce intraocular pressure.
Designed to be permanently implanted in the eye.
Other Names:
|
EXPERIMENTAL: CyPass30
CyPass Micro-Stent implantation followed by targeted delivery of 30 μl ophthalmic viscoelastic
|
Small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye in order to reduce intraocular pressure.
Designed to be permanently implanted in the eye.
Other Names:
Healon 5 ophthalmic viscoelastic used to increase the size of the aqueous drainage area created by the CyPass Micro-Stent
|
EXPERIMENTAL: CyPass60
CyPass Micro-Stent implantation followed by targeted delivery of 60 μl ophthalmic viscoelastic
|
Small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye in order to reduce intraocular pressure.
Designed to be permanently implanted in the eye.
Other Names:
Healon 5 ophthalmic viscoelastic used to increase the size of the aqueous drainage area created by the CyPass Micro-Stent
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Subjects With ≥ 20% Decrease From Baseline to 12 Months Postoperative in IOP Without Use of Ocular Hypotensive Medication
Time Frame: Baseline (Day -1), Month 12 PostOperative
|
IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and reported in millimeters of mercury (mmHg).
A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage).
One eye (study eye) contributed to the analysis.
No formal statistical hypothesis testing was planned for the study.
|
Baseline (Day -1), Month 12 PostOperative
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Subjects With Device-related Ocular Adverse Events
Time Frame: Up to Month 12 PostOperative
|
A device related adverse event (AE) was any AE that was considered to be possibly, probably, or definitely related to the device in the opinion of the investigator.
Reported categorically as intraoperative (start date on the date of surgery) and postoperative (start date after surgery).
One eye (study eye) contributed to the analysis.
No formal statistical hypothesis testing was planned for the study.
|
Up to Month 12 PostOperative
|
Mean Change From Baseline to 12 Months Postoperative in Medicated IOP
Time Frame: Baseline (Day -1), Month 12 PostOperative
|
IOP (fluid pressure inside the eye) was measured by Goldmann applanation tonometry.
A higher IOP can be a greater risk for developing glaucoma or glaucoma progression (leading to optic nerve damage).
A higher negative change indicates improvement.
One eye (study eye) contributed to the analysis.
No formal statistical hypothesis testing was planned for the study.
|
Baseline (Day -1), Month 12 PostOperative
|
Percentage of Eyes Using Ocular Hypotensive Medication at 12 Months
Time Frame: Month 12 PostOperative
|
The use of ocular hypotensive medications was assessed in subjects with at least one IOP-lowering medication at 12 Months.
One eye (study eye) contributed to the analysis.
No formal statistical hypothesis testing was planned for the study.
|
Month 12 PostOperative
|
Mean Change From Screening to 12 Months Postoperative in Number of Topical IOP-lowering Medications Used
Time Frame: Screening (Day -2), Month 12 PostOperative
|
The number of IOP lowering medications in subjects at 12 months was compared to medicated baseline.
A higher negative change indicates improvement.
One eye (study eye) contributed to the analysis.
No formal statistical hypothesis testing was planned for the study.
|
Screening (Day -2), Month 12 PostOperative
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TMI-13-01
- GLD122-P001 (OTHER: Alcon)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Open Angle Glaucoma
-
AllerganRecruiting18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA) (ARGOS)Ocular Hypertension | Open-angle GlaucomaUnited States
-
Aerie PharmaceuticalsCompletedOcular Hypertension | Open-angle Glaucoma
-
West Virginia UniversityUniversity of Pittsburgh; University of MichiganWithdrawnOpen-angle Glaucoma
-
Glaukos CorporationUnknownOpen-Angle GlaucomaSpain, Germany, Austria, Turkey
-
Alcon ResearchWithdrawnOpen-Angle Glaucoma
-
Asociación para Evitar la Ceguera en MéxicoUnknown
-
Pharmaceutical Research NetworkCompleted
-
National Eye Institute (NEI)CompletedOpen-Angle Glaucoma
Clinical Trials on CyPass Micro-Stent
-
Transcend Medical, Inc.CompletedPrimary Open Angle Glaucoma (POAG)
-
Alcon ResearchCompletedPrimary Open Angle Glaucoma | CataractUnited States
-
Transcend Medical, Inc.CompletedOpen Angle Glaucoma (OAG)Spain, Austria, Bulgaria, Germany, Italy, Poland
-
Alcon ResearchTranscend Medical, Inc.CompletedPrimary Open Angle Glaucoma (POAG)United States
-
Transcend Medical, Inc.CompletedCataract | Primary Open Angle Glaucoma (POAG)
-
Alcon ResearchTerminated
-
Glaukos CorporationCompletedGlaucoma | Glaucoma, Open-Angle | Eye DiseasesSpain, France, Armenia, Germany, Austria, Italy
-
University of Turin, ItalyCompletedPrimary Open Angle Glaucoma and Cataracts
-
New World Medical, Inc.CompletedOpen Angle GlaucomaUnited States
-
Xuzhou Central HospitalEnrolling by invitationHilar CholangiocarcinomaChina